Prelude Capital Management, LLC Graphite Bio, Inc. Transaction History

Prelude Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.24 - $2.66 $672 - $798	-300 Reduced 1.04%	28,584 $74,000
Q3 2023 Nov 14, 2023	SELL	$2.18 - $2.77 $25,405 - $32,281	-11,654 Reduced 28.75%	28,884 $71,000
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $20,844 - $28,523	8,439 Added 26.29%	40,538 $105,000
Q1 2023 May 15, 2023	SELL	$1.85 - $3.21 $3,885 - $6,741	-2,100 Reduced 6.14%	32,099 $78,000
Q4 2022 Feb 14, 2023	BUY	$2.82 - $3.59 $3,666 - $4,667	1,300 Added 3.95%	34,199 $113,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $23,806 - $35,794	8,442 Added 34.52%	32,899 $104,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $5.23 $52,337 - $127,910	24,457 New	24,457 $67,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.